Androgen deprivation therapy (ADT) has been the standard of care for treating advanced prostate cancer for many decades. Prostate cancer cells are generally androgen-dependent, and most patients with advanced disease will respond to ADT in some form or another. Androgen deprivation therapy is utilized in the suppression of testosterone production. ADT may be used as a sole or primary treatment. It is utilized in men with prostate cancer who are of advanced age, who have significant comorbidities, and who decline curative therapy (Tanagho et al., Smith’s general urology. New York: McGraw-Hill Companies, Inc., 2008). There are four methods to block androgen: (1) removal of the sources of androgens, (2) use of LHRH agonists/GnRH antagonists, (3) use of antiandrogens, and (4) inhibition of androgen synthesis.